

L4 ANSWER 4 OF 5 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
AN 93001761 EMBASE
DN 1993001761
TI The treatment of Peyronie's disease with tamoxifen.
AU Ralph D.J.; Brooks M.D.; Bottazzo G.F.; Pryor J.P.
CS Institute of Urology, Middlesex Hospital, Mortimer Street, London W1 8HH,
United Kingdom
SO British Journal of Urology, (1992) 70/6 (648-651).
ISSN: 0007-1331 CODEN: BJURAN
CY United Kingdom
DT Journal; Article
FS 028 Urology and Nephrology
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LA • English
SL English
AB This is a preliminary study of the treatment of 36 patients with
Peyronie's disease who received tamoxifen 20 mg twice daily for
3 months. An improvement occurred in 16 of 20 patients with penile pain,
in 11 of 31 patients with an erectile deformity and 12 of 35
patients had a plaque shrinkage of at least 1 cm. Some improvement
occurred in 6 of the 8 patients with a histologically confirmed
inflammatory infiltrate of the plaque but not in any of the 4 patients
without an infiltrate. The inflammatory infiltrate was found in patients
in whom the duration of the disease was less than 4 months.
CT Medical Descriptors:
*pain
*penis
*peyronie disease: DT, drug therapy
adult
aged
article
clinical article
controlled study
hot flush: SI, side effect
human
libido loss: SI, side effect
male
oral drug administration
priority journal
t lymphocyte
Drug Descriptors:
*tamoxifen: AE, adverse drug reaction
*tamoxifen: DT, drug therapy
*tamoxifen: DO, drug dose
RN (tamoxifen) 10540-29-1